Source-grounded facts extracted from Ernexa Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Andrew Jackson resigned as Chief Financial Officer at Ernexa Therapeutics Inc..
“Mr. Jackson resigned from his position as Chief Financial Officer (principal financial officer) and as an officer, director, manager or employee of the Company’s subsidiaries.”
Ernexa Therapeutics Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10.0 million (effective 2023-04-05).
“On April 5, 2023, Eterna Therapeutics Inc., a Delaware corporation (the " Company "), entered into a purchase agreement (the " Purchase Agreement ") and a registration rights agreement (the " Registration Rights Agreement ") with Lincoln Park Capital Fund, LLC (" Lincoln Park "), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock”
Ernexa Therapeutics Inc. reported full year of 2022 results: net income For the full year of 2022, net loss was $24.6 million, or $8.06 per share., EPS $8.06 per share.
“For the full year of 2022, net loss was $24.6 million, or $8.06 per share.”
Ernexa Therapeutics Inc. reported fourth quarter of 2022 results: net income Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share, EPS $1.24 per share.
“Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share.”
Ernexa Therapeutics Inc. terminated Amended Factor License Agreement with Factor valued at Terminated and superseded by Exclusive License Agreement (effective 2023-02-20).
“Effective on February 20, 2023, the Exclusive License Agreement terminated and superseded the Amended Factor License Agreement.”
Ernexa Therapeutics Inc. entered into Exclusive License Agreement with Factor Bioscience Limited valued at 20% of Sublicense Fees before Expiration Date, 30% during Renewal Term; at least $100 million in sub (effective 2023-02-20).
“On February 20, 2023, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into an exclusive license agreement (the “ Exclusive License Agreement ”) with Factor Bioscience Limited (“ Factor ”)”
Dr. Roger Sidhu resigned as Chief Medical Officer at Ernexa Therapeutics Inc..
“On January 20, 2023, Dr. Roger Sidhu, Chief Medical Officer of Eterna Therapeutics Inc., a Delaware corporation, delivered his notice of resignation, with such resignation becoming effective on January 31, 2023.”
Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“November 22, 2022 stating that the Company’s stockholders’ equity of approximately $8.8 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, fails to comply with the minimum $10.0 million stockholders’ equity requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(1)(A). The Notice provided that the Company may consider applying to transfer the listing of the Company’s common stock, par value $0.005 per share (the “ common stock ”) to The Nasdaq Capital Market, subject to the Compan”
Dr. Matthew Angel was appointed as President and Chief Executive Officer at Ernexa Therapeutics Inc..
“On December 30, 2022, the Board appointed Dr. Matthew Angel as the Company’s President and Chief Executive Officer (principal executive officer) effective January 1, 2023 (the “ Start Date ”).”
Ernexa Therapeutics Inc. terminated Termination Agreement with Torrey Pines Science Center Limited Partnership valued at $100,000 (effective 2022-11-30).
“On November 30, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a lease termination agreement (the “ Termination Agreement ”) with Torrey Pines Science Center Limited Partnership, a Delaware limited partnership (“ Landlord ”), to terminate that certain lease agreement (the “ Lease ”), dated as of March 31, 2022”
Ernexa Therapeutics Inc. entered into Registration Rights Agreement with the Purchasers (effective 2022-12-02).
“Pursuant to the Purchase Agreement, on the Closing Date, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company has agreed to prepare and file a registration statement on Form S-3 with the Securities and Exchange Commission no later than 30 days following the date on which the Company becomes eligible to use Form S-3 to register the resale of the shares of Common Stock included in the Units and the shares of Common Stock issuable upon exercise of the Warrants.”
Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors (the "Purchasers") valued at approximately $7.7 million (effective 2022-11-23).
“As previously reported, on November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of an aggregate of 2,184,950 units (collectively, the “ Units ”), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”) and (ii) two warrants, each exercisable to purchase one share of Common Stock (the “ Warrants ”), for an aggregate purchase price of approximately $7.7 million, consisting of $3.53 per Unit (inclusive of $0.125 per Warrant).”
Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $ 7.7 million (effective 2022-11-23).
“On November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of an aggregate of 2,184,950 units (collectively, the “ Units ”), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”) and (ii) two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share (the “ Warrants ”), for an aggregate purchase price of approximately $ 7.7 million”
Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“November 22, 2022, Eterna Therapeutics Inc. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s stockholders’ equity of approximately $8.8 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, fails to comply with the minimum $10.0 million stockholders’ equity requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(1)(A) (the “ Nasdaq Listing Rule ”). The Notice has no immediate effect on the listing of the Com”
Ernexa Therapeutics Inc. amended First Amendment with Factor Bioscience Limited (effective 2022-11-22).
“On November 22, 2022 (the “ Amendment Effective Date ”), Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a First Amendment (the “ Amendment ”) to the Exclusive License Agreement, dated as of April 26, 2021 (the “ Original License Agreement ,” and as amended by the Amendment, the “ Amended Factor License Agreement ”), by and among Brooklyn Immunotherapeutics LLC, a wholly owned subsidiary of the Company (“ Brooklyn LLC ”), Novellus Therapeutics Limited, a wholly owned subsidiary of the Company (“ Novellus ”), and Factor Bioscience Limited (“ Factor ”).”
Kevin D'Amour resigned as Chief Scientific Officer at Ernexa Therapeutics Inc..
“On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.”
Dr. Kevin D'Amour resigned as Chief Scientific Officer at Ernexa Therapeutics Inc..
“On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.”
Nicholas Singer was appointed as Director at Ernexa Therapeutics Inc..
“On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.”
William Wexler was appointed as Director at Ernexa Therapeutics Inc..
“On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.”
Gregory Fiore was appointed as Director at Ernexa Therapeutics Inc..
“On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.”
Matthew Angel was appointed as Director at Ernexa Therapeutics Inc..
“On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.”
Heather Redman resigned as Director at Ernexa Therapeutics Inc..
“On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.”
Erin Enright resigned as Director at Ernexa Therapeutics Inc..
“On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.”
Erich Mohr resigned as Director at Ernexa Therapeutics Inc..
“On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.”
Dennis Langer resigned as Director at Ernexa Therapeutics Inc..
“On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.”
Andrew Jackson was appointed as Chief Financial Officer at Ernexa Therapeutics Inc..
“On May 9 , 2022, the Board appointed Andrew Jackson as the Chief Finan”
Matthew Angel was appointed as interim President and Chief Executive Officer at Ernexa Therapeutics Inc..
“On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.”
Howard J. Federoff, M.D., Ph.D. resigned as Chief Executive Officer at Ernexa Therapeutics Inc..
“On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.”
Erin S. Enright was appointed as Director at Ernexa Therapeutics Inc..
“On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.”
Heather B. Redman was appointed as Director at Ernexa Therapeutics Inc..
“On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.”
Luba Greenwood resigned as Director at Ernexa Therapeutics Inc..
“On December 16, 2021, Luba Greenwood notified the board of directors of her intention to resign as a director effective as of January 1, 2022.”
Roger Sidhu was appointed as Chief Medical Officer at Ernexa Therapeutics Inc..
“On September 22, 2021, we announced that Roger Sidhu had been appointed as our Chief Medical Officer, effective September 20, 2021.”
Jay Sial was appointed as Chief Administrative Officer at Ernexa Therapeutics Inc..
“On July 13, 2021, we announced that Jay Sial, had been appointed as our Chief Administrative Officer, effective July 15, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.